Author Correction: Scribble mis-localization induces adaptive resistance to KRAS G12C inhibitors through feedback activation of MAPK signaling mediated by YAP-induced MRAS - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Correction: Scribble mis-localization drives adaptive resistance to KRAS G12C inhibitors via YAP-induced MRAS and feedback activation of MAPK signaling

  • By

  • Yuta Adachi

  • Ryo Kimura

  • Kentaro Hirade

  • Shogo Yanase

  • Yuki Nishioka

  • Natsumi Kasuga

  • Rui Yamaguchi

  • Hiromichi Ebi

  • October 19, 2026

Share

Objective:

To correct an error in the Source Data and Extended Data Fig. 1f of the original Nature Cancer article.

Approach:
  • Error identified: Three NCI-H358 snail control values were duplicated and substituted for the NCI-H358 ZEB1 control values during preparation of the Source Data.
  • Correction: The figure and Source Data were corrected in the article’s HTML and PDF versions; the original figure is included as Supplementary Information for comparison.
Key Findings:
  • Incorrect values appeared in both the Source Data and the corresponding Extended Data Fig. 1f panel.
Interpretation:

This amendment reports a clerical error and its correction.

Conclusion:

Published online 5 June 2023; corrects the Nature Cancer article at https://doi.org/10.1038/s43018-023-00575-2.

Sources:

Original Source(s)

Author Correction: Scribble mis-localization induces adaptive resistance to KRAS G12C inhibitors through feedback activation of MAPK signaling mediated by YAP-induced MRAS

  • by Yuta Adachi, Ryo Kimura, Kentaro Hirade, Shogo Yanase, Yuki Nishioka, Natsumi Kasuga, Rui Yamaguchi, Hiromichi Ebi

  • October 19, 2026

Related Content

Screening strategies for the early detection of non-cardia gastric cancer in low- to moderate-prevalence regions: Asia-Pacific gastroesophageal cancer congress consensus 2026

Depth of Invasion as a Predictor of Contralateral Nodal Metastasis in Lateralized Oral Tongue Squamous Cell Carcinomas

2026 ASCO Breast Cancer Highlights: Neo-Healer

Harold Burstein, MD, PhD, and Adrienne Waks, MD discuss the new Neo-Healer trial in HER2+ breast cancer.

  • October 15, 2026

  • 1 min